Comparison of the epidermal growth factor receptor protein expression between primary non-small cell lung cancer and paired lymph node metastases: Implications for targeted nuclide radiotherapy

Journal of Experimental and Clinical Cancer Research

Volumn 29, Issue 1, 2010, Pages

  Rao, Chuangzhou ^a,b   Hu, Qiongge ^a   Ma, Jianhua ^a   Li, Jian ^c   Zhang, Chen ^b   Shen, Li ^a   Wei, Qichun ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Second Hospital of Ningbo   (China)

^c NINGBO FIRST HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; EVALUATION; LUNG TUMOR; METABOLISM; MIDDLE AGED; SCINTISCANNING;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 77649307925     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-29-7     Document Type: Article

References (28)

1. Cancer statistics 2009. A Jemal R Siegel E Ward Y Hao J Xu MJ Thun, CA Cancer J Clin 2009 59 225 249 10.3322/caac.20006 19474385
2. Treatment of advanced non-small cell lung cancer. HH Hansen, BMJ 2002 325 452 453 10.1136/bmj.325.7362.452 12202311
3. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. P Yang MS Allen MC Aubry JA Wampfler RS Marks ES Edell S Thibodeau AA Adjei J Jett C Deschamps, Chest 2005 128 452 462 10.1378/chest.128.1.452 16002972
4. Chemotherapy of lung cancer. DC Ihde, N Engl J Med 1992 327 1434 1441 1328881
5. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. DG Pfister DH Johnson CG Azzoli W Sause TJ Smith S Baker Jr J Olak D Stover JR Strawn AT Turrisi MR Somerfield American Society of Clinical Oncology, J Clin Oncol 2004 22 330 353 10.1200/JCO.2004.09.053 14691125
6. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC). E Felip RA Stahel N Pavlidis ESMO Guidelines Task Force, Ann Oncol 2005 16 28 29 10.1093/annonc/mdi821 15888743
7. Treatment paradigms for advanced stage non-small cell lung cancer in the era of multiple lines of therapy. TE Stinchcombe MA Socinski, J Thorac Oncol 2009 4 243 250 10.1097/JTO.0b013e31819516a6 19179904
8. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. JH Schiller D Harrington CP Belani C Langer A Sandler J Krook J Zhu DH Johnson Eastern Cooperative Oncology Group, N Engl J Med 2002 346 92 98 10.1056/NEJMoa011954 11784875 (Pubitemid 34438899)
9. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. GV Scagliotti P Parikh J von Pawel B Biesma J Vansteenkiste C Manegold P Serwatowski U Gatzemeier R Digumarti M Zukin JS Lee A Mellemgaard K Park S Patil J Rolski T Goksel F de Marinis L Simms KP Sugarman D Gandara, J Clin Oncol 2008 26 3543 3551 10.1200/JCO.2007.15.0375 18506025
10. Erlotinib in previously treated non-small-cell lung cancer. FA Shepherd J Rodrigues Pereira T Ciuleanu EH Tan V Hirsh S Thongprasert D Campos S Maoleekoonpiroj M Smylie R Martins M van Kooten M Dediu B Findlay D Tu D Johnston A Bezjak G Clark P Santabrbara L Seymour National Cancer Institute of Canada Clinical Trials Group, N Engl J Med 2005 353 123 132 10.1056/NEJMoa050753 16014882 (Pubitemid 41058344)
11. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. R Pérez-Soler A Chachoua LA Hammond EK Rowinsky M Huberman D Karp J Rigas GM Clark P Santabrbara P Bonomi, J Clin Oncol 2004 22 3238 3247 10.1200/JCO.2004.11.057 15310767
12. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). M Fukuoka S Yano G Giaccone T Tamura K Nakagawa JY Douillard Y Nishiwaki J Vansteenkiste S Kudoh D Rischin R Eek T Horai K Noda I Takata E Smit S Averbuch A Macleod A Feyereislova RP Dong J Baselga, J Clin Oncol 2003 21 2237 2246 10.1200/JCO.2003.10.038 12748244
13. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. MG Kris RB Natale RS Herbst TJ Lynch Jr D Prager CP Belani JH Schiller K Kelly H Spiridonidis A Sandler KS Albain D Cella MK Wolf SD Averbuch JJ Ochs AC Kay, JAMA 2003 290 2149 2158 10.1001/jama.290.16.2149 14570950 (Pubitemid 37432975)
14. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. R Pirker JR Pereira A Szczesna J von Pawel M Krzakowski R Ramlau I Vynnychenko K Park CT Yu V Ganul JK Roh E Bajetta K O'Byrne F de Marinis W Eberhardt T Goddemeier M Emig U Gatzemeier FLEX Study Team, Lancet 2009 373 1525 1531 10.1016/S0140-6736(09) 60569-9 19410716
15. Tumour therapy with radionuclides: assessment of progress and problems. J Carlsson E Forssell Aronsson SO Hietala T Stigbrand J Tennvall, Radiother Oncol 2003 66 107 117 10.1016/S0167-8140(02)00374-2 12648782
16. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. G Fontanini M De Laurentiis S Vignati, Clin Cancer Res 1998 4 241 249 9516978
17. Differential expression of the epidermal growth factor receptor and its ligands in primary nonsmall cell lung cancers and adjacent benign lung. V Rusch J Baselga C Cordon-Cardo J Orazem M Zaman S Hoda J McIntosh J Kurie E Dmitrovsky, Cancer Res 1993 53 2379 2385 7683573
18. Epidermal Growth Factor Receptor, Cyclooxygenase-2, and BAX Expression in the Primary Non-Small Cell Lung Cancer and Brain Metastases. I Milas R Komaki T Hachiya R Bubb J Ro L Langford R Sawaya J Putnam P Allen J Cox T McDonnell W Brock W Hong J Roth L Milas, Clinical Cancer Research 2003 9 1070 1076 12631609
19. WD Travis E Brambilla HK Muller-Hermelink CC Harris, Pathology and Genetics of Tumors of the Lung, Pleura, Thymus and Heart Lyon: IARC Press 2004
20. LH Sobin C Wittekind, TNM Classification of Malignant Tumors New York: Wiley-Liss 2002
21. EGFR, HER2, and HER3 expression in laryngeal primary tumors and corresponding metastases. Q Wei L Sheng Y Shui Q Hu H Nordgren J Carlsson, Ann Surg Oncol 2008 15 1193 1201 10.1245/s10434-007-9771-3 18172732
22. EGFR and HER2 expression in primary cervical cancers and corresponding lymph node metastases: Implications for targeted radiotherapy. L Shen Y Shui X Wang L Sheng Z Yang D Xue Q Wei, BMC Cancer 2008 8 232 10.1186/1471-2407-8-232 18700025
23. EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases. Q Wei L Chen L Sheng H Nordgen K Wester J Carlsson, Int J Oncol 2007 31 493 499 17671674
24. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. F Cappuzzo FR Hirsch E Rossi S Bartolini GL Ceresoli L Bemis J Haney S Witta K Danenberg I Domenichini V Ludovini E Magrini V Gregorc C Doglioni A Sidoni M Tonato WA Franklin L Crino PA Bunn Jr M Varella-Garcia, J Natl Cancer Inst 2005 97 643 655 15870435 (Pubitemid 40812628)
25. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-smallcell lung cancer. FR Hirsch M Varella-Garcia PA Bunn Jr WA Franklin R Dziadziuszko N Thatcher A Chang P Parikh JR Pereira T Ciuleanu J von Pawel C Watkins A Flannery G Ellison E Donald L Knight D Parums N Botwood B Holloway, J Clin Oncol 2006 24 5034 5042 10.1200/JCO.2006.06.3958 17075123
26. Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors. A Italiano FB Vandenbos J Otto J Mouroux D Fontaine PY Marcy N Cardot A Thyss F Pedeutour, Ann Oncol 2006 17 981 985 10.1093/annonc/mdl038 16524970
27. Differential Expression of Biomarkers in Primary Non-small Cell Lung Cancer and Metastatic Sites. C Gomez-Roca CM Raynaud F Penault-Llorca O Mercier F Commo L Morat L Sabatier P Dartevelle E Taranchon B Besse P Validire A Italiano JC Soria, J Thorac Oncol 2009 4 1212 1220 10.1097/JTO.0b013e3181b44321
28. Phenotype of Bone Metastases of Non-Small Cell Lung Cancer: Epidermal Growth Factor Receptor Expression and K-RAS Mutational Status. G Badalian T Barbai E Rsá K Derecskei M Szendri J Tímr, Pathol Oncol Res 2007 13 99 104 10.1007/BF02893484 17607370